Advertisement
ISTA's President and Chief Executive Officer, Vicente Anido, Jr., Ph.D.,will provide an update on the Company's commercial and clinical progress. Toaccess the live audio broadcast or the subsequent archived recording log ontohttp://www.istavision.com. Please connect to the website several minutes priorto the start of the conference call to ensure adequate time for any softwaredownload that may be necessary.
Advertisement
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA'sproducts and product candidates addressing the $3.2 billion U.S. prescriptionophthalmic industry include therapies for inflammation, ocular pain, glaucoma,allergy, and dry eye. The Company currently markets three products and isdeveloping a strong product pipeline to fuel future growth and market share.The Company's product development and commercialization strategy is to launcha new product every 12 to 18 months, thereby continuing its growth to becomethe leading niche ophthalmic pharmaceutical company in the U.S. For additionalinformation regarding ISTA, please visit ISTA Pharmaceuticals' website athttp://www.istavision.com.
SOURCE ISTA Pharmaceuticals, Inc.
